HERE is a growing interest in the ability of neural grafts to replace the function of degenerated brain cells. Clinical trials in which fetal human 10, 13, 31 and porcine 9 mesencephalon were used as a source of dopaminergic neurons have been conducted in patients with Parkinson's disease. These patients face the problem of graft rejection. The immunology of neural transplantation is an emerging field. 22, 25, 30 The brain is an "immunologically privileged" site and foreign antigens placed into the brain are not rejected as fast as those placed in peripheral areas. 19 In animal models, however, it has been repeatedly shown that xenografts (tissue from different species) are strongly rejected within the host brain. 16, 17 The most widely used treatment to prevent neural graft rejection in animal models and clinical trials is a regimen of cyclosporin. 21 Unfortunately this drug has well-known nephrotoxic and neurotoxic side effects. 2, 3 In an attempt to find alternative immunosuppressive techniques, investigators have tested other compounds. 11, 20, 23, 24, 33 In this paper we compare the efficacy of short-and long-term immunosuppression therapy using cyclosporin with that of short-term (2-week) treatment using a monoclonal antibody (mAb) against the interleukin (IL)-2 receptor, anti-CD25 mAb, to prolong the duration of neural xenograft survival and function in a rodent model.
Materials and Methods

Animal Preparation
The dopamine-innervated striatum in adult male Wistar rats (200-250 g each) was unilaterally lesioned by administering injections of 6-hydroxydopamine HCl (8 g in 4 l of saline with 0.02% ascorbate over an 8-minute period) into the right median forebrain bundle (Ϫ4.4 mm anterior to the bregma, 1 mm right of the midline, and Ϫ7.8 from the dura with the incisor placed 2.3 mm below the interaural line). Lesioned animals exhibit a quantifiable, rotational behavior that correlates to the loss of dopamine neurons and can be exaggerated by administration of amphetamine. 28, 29 Three weeks later, circling behavior in response to d-methamphetamine HCl (2.5 mg/kg administered intraperitoneally) was quantified using automated rotameters. The number of rotations (360˚) each rat made during 1 hour was counted and the net ipsiversive rotations were calculated. Only animals rotating more than six turns per minute were used in the study. The animals were divided into four groups of 20 with similar rotational scores. Group 1 received no immunosuppression therapy; Group 2 received daily intraperitoneal injections of 10 mg/kg cyclosporin A for 2 weeks; Group 3 received daily intraperitoneal injections of 10 mg/kg cyclosporin A for 8 weeks; and Group 4 received daily intraperitoneal injections of 1 mg/kg anti-CD25 mAb for 2 weeks. The anti-CD25 mAb was purified from ascites produced when the NDS 63 myeloma cell line was grown as intraperitoneal tumors in (BALB/c ϫ DBA/2) F1 hybrid mice.
Preparation of Xenografts
The xenografts were prepared by dissecting out the ventral mesencephalon from fetal CD-1 mice (crown-rump length 10-12 mm) and making a cell suspension. Fragments of mesencephalon were incubated in 0.1% trypsin for 20 minutes at 37˚C and then washed four times in medium (RPMI, 0.004% DNAse, 0.0125% soybean antitrypsin, and 15 mM MgSO 4 ). Fragments were resuspended in 100 l medium and titrated through a Pasteur pipette to make a cell suspension. Each animal received two 3-l injections of xenograft cell suspension into the dopamine-denervated striatum (coordinates with the incisor bar set at Ϫ2.3 mm were: 1 mm anterior to the bregma, 2.8 mm lateral to the midline, and 5 and 4.1 mm deep with respect to the dura). Following transplantation, the cell viability of the suspension was estimated by using the trypan blue dye exclusion technique and found to be greater than 10 7 /ml (clumps of cells made exact calculation difficult).
Statistical Analysis
Rotational behavior was quantified every 4 weeks for 16 weeks. Net ipsiversive rotations for each animal were counted and recorded as a percentage of their pretransplant values (Fig. 1) . The mean scores for each group at each time point were compared using analysis of variance (ANOVA). Groups 2, 3, and 4 were compared with the control animals (Group 1) at 16 weeks by contrast within the ANOVA. A Bonferroni correction was introduced to correct for multiple comparisons.
At 16 weeks, all animals were deeply anesthetized, killed, and perfused with intracardiac heparinized saline; and their brains were removed and quick-frozen in optimum-cutting-temperature embedding compound. Twelve-micron cryostat sections were prepared for indirect immunohistochemical analysis by following the technique of Barclay.
1 The primary antibody, MCA02, was used against the Thy-1.2 antigen found on murine central nervous system neurons. 18 The secondary antibody, AACO7P, was conjugated to horseradish peroxidase, revealed by using diaminobenzidine, and counterstained with cresyl violet. The histological characteristics were scored as "positive" or "negative," depending on the presence or absence of staining for the murine neuronal marker, Thy-1.2. Individual groups were compared in 2 ϫ 2 tables by using Fisher's exact test with a Bonferroni correction introduced for multiple comparisons. Statistics were calculated using commercially available software.
Sources of Supplies and Equipment
The xenografts were obtained from CD-1 mice, available from Charles River Laboratories (Montreal, Quebec, Canada). The cyclosporin A (SandImmune) was provided by Sandoz (now Novartis Canada Inc., Mississauga, Ontario, Canada). The automated rotameters used to quantify the rats' rotational behaviors were obtained from Columbus Instruments (Columbus, OH). The optimum-cutting-temperature compound was provided by Sakura 
Results
The rotational scores are shown in Fig. 1 . A significant difference between groups (p Ͻ 0.001) was found using ANOVA. Individual comparisons at 16 weeks after transplant showed no significant reduction in rotational behavior for Group 2 (cyclosporin for 2 weeks) compared with Group 1 (control animals with no immunosuppression). Group 3 (cyclosporin for 8 weeks) had significantly reduced rotational behavior compared with Group 1 (p Ͻ 0.01). Group 4 (anti-CD25 mAb for 2 weeks) had significantly reduced rotational behavior compared with Group 1 (p Ͻ 0.05).
Histological examples of the graft site 16 weeks after transplant are shown in Fig. 2 . These examples show "positive" or "negative" staining for the xenograft neuronal marker, Thy-1.2. We did not attempt to quantify cellular immune rejection. None of the animals in Group 1 (controls) had surviving xenografts. Surviving xenografts were found in 5% of the animals in Group 2, 56% of the animals in Group 3, and 53% of the animals in Group 4. Most surviving grafts, however, showed evidence of ongoing rejection, with abundant lymphocytic infiltration. Xenograft survival at 16 weeks was significantly better in the long-term cyclosporin therapy group (p Ͻ 0.001) and those treated with anti-CD25 mAb (p Ͻ 0.001) compared with control animals that did not receive immunosuppression therapy.
During the experiment, two animals that received a long-term course of cyclosporin developed infections, re- . quiring that they be killed prematurely. None of the animals treated with anti-CD25 mAb developed a recognized infection.
Discussion
Human fetal neural grafts have been reported to restore some motor functions in patients with Parkinson's disease. 13, 31 Two National Institutes of Health-funded, prospective clinical trials are currently underway to evaluate this technique further. If neural grafting moves from experimental research to clinical practice, the immunology of neural graft rejection will become of paramount importance to the neurosurgeon. The brain is an immunologically privileged site. 19 Foreign grafts transplanted into the brain are rejected more slowly than when transplanted to other sites within the body. This is likely due to the reduced efficiency of the afferent arc of the immune system within the brain. 25, 30 This privilege, however, is far from absolute and numerous studies have shown that neural xenografts are eventually rejected by the host. 22 To prolong neural xenograft (and allograft) survival, immunosuppression of the host animal has been used. Cyclosporin A is the most common immunosuppressant. 4, 6 It binds an intracellular receptor, cyclophilin, and then inhibits calcineurin. 15 Inhibition of calcineurin results in the failure to activate the genes for IL-2, IL-4, and the CD40 ligand. Interleukin-2 is responsible for differentiating Thelper and T-cytotoxic precursors into effector cells and driving activated T cells through the G 1 and S phases into mitosis. Unfortunately, cyclosporin A therapy is accompanied by protean side effects including nephrotoxicity, seizures, and encephalopathy. 3, 12 In an attempt to find alternate means of effecting immunosuppression, researchers have used a variety of different agents. Other immunosuppressant drugs include SandImmune Neoral, FK 506, mycophenolic acid, rapamycin, brequinar, lefluamide, and deoxyspergualine. 5, 14 Monoclonal antibodies against specific elements of the immune system, such as the CD4, CD25, CD54, and major histocompatibility complex Class I surface molecules, have also been used for immunosuppression. 8, 16, 17, 21 These mAbs selectively impair components of the immune system in an attempt to block graft rejection without impairing all functions of the immune system (such as infection defense).
The interaction between IL-2 and its receptor, CD25, is required for the generation of cytotoxic T cells and for Tcell proliferation. Because T cells are crucial to neural xenograft rejection, these antibodies should selectively interfere with the rejection process. 25, 30 In this experiment, the anti-CD25 mAb was effective in prolonging neural xenograft survival.
Several points rise out of this work. First, it is clear that short-term immunosuppression achieved with cyclosporin (Group 2) is insufficient for prolonged neural xenograft survival. Although the blood-brain barrier is reconstituted 2 weeks after grafting, 7 this did not help the xenografts survive. Rejection was swift and complete. All xenografts were nonfunctioning less than 2 weeks after the cyclosporin therapy ceased.
Second, rejection following long-term immunosuppression achieved with cyclosporin (Group 2) also occurred, but was delayed. Half of the xenografts survived 8 weeks beyond the termination of cyclosporin therapy. This suggests that neural xenografts are susceptible to a prolonged immune attack and that any clinical trial may have to use induced immunosuppression indefinitely. This is different from allograft data from which one can conclude that long-term immunosuppression may not be required. et al., 11 showed that daily treatment with high-dose methylprednisolone (30 mg/kg) can prevent murine xenograft rejection in the striatum of adult rats for up to 6 weeks. This suggests that any clinical trial of neural xenografts may benefit from at least a 2-week regimen of antiinflammatory medication.
Fourth, short-term treatment with anti-CD25 mAb prolonged xenograft survival. This treatment would have little effect on the early postsurgical inflammatory response or any preformed antibodies against the xenograft. It is likely, therefore, that these mechanisms are not the major contributor of early graft rejection in this model.
Fifth, although cyclosporin and anti-CD25 mAb both block IL-2 function, the effects following anti-CD25 mAb treatment are significantly more prolonged. This could occur because the antibody is cleared more slowly than the cyclosporin. At 16 weeks, however, there was no immunohistochemical evidence of the anti-CD25 mAb. Sections of the host animals' xenograft, spleen, and lymph nodes stained for mouse immunoglobulin were negative (data not shown). Tellides and associates 26 postulated that the anti-CD25 mAb NDS 63 functioned by target-cell inhibition, but their sampling of T cells was done only 5 days into treatment. Another mechanism of immunosuppression caused by this anti-CD25 mAb could be targetcell depletion. Activated T cells prevented from proliferating may be removed from the circulation. Deletion of these xenograft-specific T cells could potentially lead to a state of tolerance. Wood and colleagues 32 demonstrated an indefinite length of survival by using this antibody in neural allografts grafted into the rat brain. Cyclosporin, on the other hand, functions by preventing these xenograftspecific T cells from becoming activated. Nonactivated T cells would not be deleted from the immune system and could be activated once the cyclosporin therapy is discontinued. Their access to the xenograft may be delayed (if all perisurgical inflammation has settled), but they ultimately effect rejection.
Conclusions
Short-term (2 weeks) immunosuppression achieved with a course of anti-CD25 mAb can prolong neural xenograft survival and function in the rodent. Its effects on xenograft survival are better than those produced by a short-term regimen of cyclosporin and similar to those of a long-term (8 weeks) regimen of cyclosporin. Although both therapies interfere with IL-2 pathways, neither resulted in neural xenograft survival in all animals.
